NVS vs. GS
NVS (Novartis AG) and GS (The Goldman Sachs Group, Inc.) are both stocks. NVS operates in Drug Manufacturers - General (Healthcare), while GS operates in Capital Markets (Financial Services). Over the past 10 years, NVS returned 11.14%/yr vs 24.48%/yr for GS. At a 0.26 correlation, their price movements are largely independent.
Performance
NVS vs. GS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVS achieves a 14.40% return, which is significantly lower than GS's 22.08% return. Over the past 10 years, NVS has underperformed GS with an annualized return of 11.14%, while GS has yielded a comparatively higher 24.48% annualized return.
NVS
- 1D
- -0.55%
- 1M
- 3.37%
- YTD
- 14.40%
- 6M
- 18.98%
- 1Y
- 32.05%
- 3Y*
- 19.57%
- 5Y*
- 14.77%
- 10Y*
- 11.14%
GS
- 1D
- 2.62%
- 1M
- 12.54%
- YTD
- 22.08%
- 6M
- 20.84%
- 1Y
- 76.70%
- 3Y*
- 49.31%
- 5Y*
- 25.98%
- 10Y*
- 24.48%
NVS vs. GS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVS Novartis AG | 14.40% | 46.95% | 0.02% | 16.14% | 8.06% | -3.65% | 3.34% | 13.92% | 5.95% | 19.42% |
GS The Goldman Sachs Group, Inc. | 22.08% | 56.64% | 52.03% | 15.91% | -7.87% | 47.61% | 17.45% | 40.48% | -33.53% | 7.73% |
Correlation
The correlation between NVS and GS is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.17 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.23 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since May 4, 1999 | 0.26 |
Fundamentals
NVS:
$293.28B
GS:
$327.33B
NVS:
$6.99
GS:
$57.41
NVS:
21.90
GS:
18.51
NVS:
1.48
GS:
2.40
NVS:
5.29
GS:
3.02
NVS:
7.62
GS:
2.66
NVS:
$56.05B
GS:
$110.77B
NVS:
$42.19B
GS:
$61.53B
NVS:
$22.40B
GS:
$24.94B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVS vs. GS — Risk / Return Rank
NVS
GS
NVS vs. GS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NVS) and The Goldman Sachs Group, Inc. (GS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVS | GS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.12 | ||
| Sortino ratioReturn per unit of downside risk | -1.09 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.41 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | 2.43 | 3.80 | -1.37 |
| Martin ratioReturn relative to average drawdown | 5.88 | 12.61 | -6.73 |
Loading charts...
Drawdowns
NVS vs. GS - Drawdown Comparison
The maximum NVS drawdown since its inception was -42.10%, smaller than the maximum GS drawdown of -78.84%. Use the drawdown chart below to compare losses from any high point for NVS and GS.
Loading charts...
Drawdown Indicators
| NVS | GS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -42.10% | -78.84% | +36.74% |
Max Drawdown (1Y)Largest decline over 1 year | -12.65% | -19.42% | +6.77% |
Max Drawdown (3Y)Largest decline over 3 years | -19.95% | -30.90% | +10.95% |
Max Drawdown (5Y)Largest decline over 5 years | -20.42% | -32.84% | +12.42% |
Max Drawdown (10Y)Largest decline over 10 years | -26.03% | -48.75% | +22.72% |
Current DrawdownCurrent decline from peak | -6.46% | -2.73% | -3.73% |
Average DrawdownAverage peak-to-trough decline | -10.92% | -22.65% | +11.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.23% | 5.84% | -0.61% |
Volatility
NVS vs. GS - Volatility Comparison
The current volatility for Novartis AG (NVS) is 7.18%, while The Goldman Sachs Group, Inc. (GS) has a volatility of 11.84%. This indicates that NVS experiences smaller price fluctuations and is considered to be less risky than GS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVS | GS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.18% | 11.84% | -4.66% |
Volatility (6M)Calculated over the trailing 6-month period | 14.96% | 23.47% | -8.51% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.02% | 28.55% | -7.53% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 18.89% | 28.10% | -9.21% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 19.64% | 29.87% | -10.23% |
Dividends
NVS vs. GS - Dividend Comparison
NVS's dividend yield for the trailing twelve months is around 3.12%, more than GS's 1.60% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GS The Goldman Sachs Group, Inc. | 1.60% | 1.59% | 2.01% | 2.72% | 2.62% | 1.70% | 1.90% | 1.80% | 1.89% | 1.14% | 1.09% | 1.41% |
NVS Novartis AG | 3.12% | 2.90% | 3.84% | 3.44% | 3.70% | 3.86% | 3.22% | 3.03% | 3.47% | 3.24% | 3.73% | 3.10% |
Financials
NVS vs. GS - Financials Comparison
This section allows you to compare key financial metrics between Novartis AG and The Goldman Sachs Group, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVS vs. GS - Profitability Comparison
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.
GS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported a gross profit of 16.91B and revenue of 17.23B. Therefore, the gross margin over that period was 98.2%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.
GS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported an operating income of 6.49B and revenue of 17.23B, resulting in an operating margin of 37.7%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.
GS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported a net income of 5.63B and revenue of 17.23B, resulting in a net margin of 32.7%.
Frequently Asked Questions
NVS and GS have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GS has higher volatility (11.84%) compared to NVS (7.18%). In terms of maximum drawdown, NVS dropped -42.10% vs GS's -78.84%.
GS currently has the higher Sharpe Ratio (2.59 vs 1.47), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVS and GS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer